Cytodrox

Composition

Each capsule contains
Hydroxyurea USP 500 mg

Indication And Usage

significant tumor response to Cytodrox has been demonstrated in elanoma, resistant chronic myelocytic leukamia, and recurrent, metastatic, or inoperable carcinoma of the ovary.
Cytodrox used concomittently with irradiation therapy is intented for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip.

Dosage And Administration

Because of the rarity of melanoma, resistant chronic myelocyticleukamia, carcinoma of the ovary, and carcinoma of the head and neck in children, dosage regimens have not been established. All dosage should be based on the patients' actual or ideal weight, whichever is less.